Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

@article{QuintsCardama2010PreclinicalCO,
  title={Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.},
  author={Alfonso Quint{\'a}s-Cardama and Kris Vaddi and Phillip Liu and Taghi Manshouri and Jun Li and Peggy A. Scherle and Eian Caulder and Xiaoming Wen and Yanlong Li and Paul Waeltz and Mark J. Rupar and Timothy C. Burn and Yvonne Lo and Jennifer A Kelley and Maryanne Covington and Stacey Shepard and James D. Rodgers and Patrick J. Haley and Hagop A Kantarjian and Jordan S. Fridman and Srdan Verstovsek},
  journal={Blood},
  year={2010},
  volume={115 15},
  pages={3109-17}
}
Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy. Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs. Most patients with primary myelofibrosis have elevated… CONTINUE READING
Highly Influential
This paper has highly influenced 29 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 245 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Small molecule inhibitors of JAK1/2 improve physiological and functional measures of cancer-associated cachexia [abstract

  • JS Fridman, E Caulder, X Wen
  • Proc Am Assoc Cancer Res
  • 2009

The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2 [abstract

  • A Tefferi, H Kantarjian, AD Pardanani
  • Blood
  • 2008

Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders [abstract

  • J Fridman, R Nussenzveig, P Liu
  • Blood .
  • 2007

Similar Papers

Loading similar papers…